87736-74-1

Basic information

• Product Name: 4-TBDMS-HYDROXYMETHYLBROMOBENZENE
• Synonyms: 4-TBDMS-HYDROXYMETHYLBROMOBENZENE;1-Bromo-4-[[(tert-butyldimethylsilyl)oxy]methyl]benzene;(4-BroMobenzyl)oxy](tert-butyl)diMethylsilane;1-BroMo-4-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-benzene;4-(tert-ButyldiMethylsilyloxyMethyl)broMobenzene;4-BroMobenzyl diMethyl-tert-butylsilyl Ether;Benzene, 1-broMo-4-[[[(1,1-diMethylethyl)diMethylsilyl]oxy]Methyl]-;[(4-Bromobenzyl)oxy](tert-butyl)dimethylsilane
• CAS NO: 87736-74-1
• Molecular Formula: C₁₃H₂₁BrOSi
• Molecular Weight: 301.29
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 87736-74-1.mol

Chemical Properties

• Boiling Point: 338.833°C at 760 mmHg
• Flash Point: 158.721°C
• Appearance: /
• Density: 1.145
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane, Diethyl Ether, Methanol
• CAS DataBase Reference: 4-TBDMS-HYDROXYMETHYLBROMOBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-TBDMS-HYDROXYMETHYLBROMOBENZENE(87736-74-1)
• EPA Substance Registry System: 4-TBDMS-HYDROXYMETHYLBROMOBENZENE(87736-74-1)

Safety Data

• Hazardous Substances Data: 87736-74-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-TBDMS-HYDROXYMETHYLBROMOBENZENE is used as a key intermediate in the synthesis of aromatic bisphosphonates, which are important inhibitors of geranylgeranyl diphosphate synthase. This application is crucial in the development of drugs targeting various diseases, including cancer and metabolic disorders, due to the role of geranylgeranyl diphosphate synthase in isoprenoid biosynthesis pathways.
In the synthesis of aromatic bisphosphonates, 4-TBDMS-HYDROXYMETHYLBROMOBENZENE serves as a versatile building block that can be further functionalized to create a range of bioactive compounds. The presence of the TBDMS group provides an opportunity for selective deprotection, enabling the introduction of various functional groups at the hydroxymethyl position, which can significantly influence the biological activity of the final product.
Additionally, the bromo substituent on the benzene ring allows for cross-coupling reactions, facilitating the formation of carbon-carbon bonds with other organic fragments. This reactivity is essential for the construction of complex molecular architectures found in potential drug candidates.
Overall, 4-TBDMS-HYDROXYMETHYLBROMOBENZENE is a valuable synthetic intermediate in the pharmaceutical industry, playing a critical role in the development of novel therapeutic agents targeting geranylgeranyl diphosphate synthase and other related enzymes. Its unique structural features and reactivity make it an essential component in the design and synthesis of innovative drugs with potential applications in treating various diseases.

InChI:InChI=1/C13H21BrOSi/c1-13(2,3)16(4,5)11-6-7-12(14)10(8-11)9-15/h6-8,15H,9H2,1-5H3

Upstream product

• 873-75-6 4-bromobenzenemethanol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 108-48-5 2,6-dimethylpyridine 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 288-32-4 1H-imidazole 
• 7732-18-5 water 
• 75-05-8 acetonitrile 
• 156185-88-5 3-amino-2(S)-phenylsulfonylaminopropionic acid 

Downstream Products

• 228267-27-4 (3R)-1-(4-tert-butyldimethylsiloxymethylphenyl)-3,4-O-isopropylidene-3,4-dihydroxybutanol 
• 392235-05-1 (1S,3aS,5S,7aR)-1-hydroxymethyl-5-(4-tert-butyldimethylsilyloxymethylphenyl)-7a-methylperhydroinden-3a,5-diol 
• 252949-06-7 C₃₁H₄₀O₄SSi 
• 630407-57-7 7-[4-(tert-butyidimethylsilyloxymethyl)benzenesulfonyl]-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 803730-88-3 tert-butyldimethyl[(4-thien-2-ylbenzyl)oxy]silane 
• 414869-62-8 O-tert-butyldimethylsilyl-4-allyldimethylsilylbenzyl ether 
• 262846-35-5 4-(tert-butyl-dimethyl-silanyloxy)-2-{[4-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-hydroxy-methyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 234766-59-7 C₇₂H₁₃₂O₄Si₉ 
• 160744-60-5 4-((tert-butyldimethylsilyloxy)methyl)benzaldehyde 
• 131230-76-7 4-[(tert-butyldimethylsilyloxy)methyl]aniline 
• 204505-22-6 1-[4-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-3-{2-[1-methoxy-meth-(Z)-ylidene]-cyclohexyl}-propan-1-one 
• 148064-90-8 methyl 4-<<(tert-butyldimethylsilyl)oxy>methyl>dithiobenzoate 
• 87736-75-2 1-<4-<(tert-butyldimethylsilyloxy)methyl>phenyl>-2,2,2-trifluoro-1-ethanone 
• 737796-39-3 (Z)-[4'-(2-biphenyl-4-ylvinyl)-biphenyl-4-ylmethoxy]-tert-butyldimethylsilane 

Relevant articles and documents

Charge-tagged polar phosphine ligands in Pd-catalysed reactions in aqueous and ionic media

A new range of polar imidazolium and phosphate-containing ligands was synthesised from readily available starting materials in high yielding multi-step transformations. These ligands were used to generate Pd catalysts for Suzuki and Heck C–C coupling reac

N3-Substituted thymidine analogues III: Radiosynthesis of N 3-[(4-[18F]fluoromethyl-phenyl)butyl]thymidine ([ 18F]-FMPBT) and N-[(4-[18F]fluoromethyl-phenyl)pentyl] thymidine ([18F]-FMPPT)

Radiosyntheses of two N3-substituted thymidine analogues, N 3-[(4[18F]fluoromethyl-phenyl)butyl]thymidine ([ 18F]-FMPBT) and N3-[(4[18F]fluoromethyl-phenyl) pentyl]thymidine ([18

Iron-Catalyzed Ring Expansion of Cyclobutanols for the Synthesis of 1-Pyrrolines by Using MsONH3OTf

The synthesis of 1-pyrrolines from cyclobutanol derivatives and an aminating reagent (MsONH3OTf) has been developed. This one-pot procedure achieves C–N bond/C═N bond formation via ring expansion. A series of 1-pyrroline derivatives are synthes

Design, synthesis, in vitro and in vivo evaluation of heterobivalent sifalin-modified peptidic radioligands targeting both integrin αv β3 and the mc1 receptor—suitable for the specific visualization of melanomas?

Combining two peptides addressing two different receptors to a heterobivalent peptidic ligand (HBPL) is thought to enable an improved tumor-targeting sensitivity and thus tumor visu-alization, compared to monovalent peptide ligands. In the case of melanoma, the Melanocortin-1 receptor (MC1R), which is stably overexpressed in the majority of primary malignant melanomas, and integrin αv β3, which is involved in lymph node metastasis and therefore has an important role in the transition from local to metastatic disease, are important target receptors. Thus, if a radiolabeled HBPL could be developed that was able to bind to both receptor types, the early diagnosis and correct staging of the disease would be significantly increased. Here, we report on the design, synthesis, radiolabeling and in vitro and in vivo testing of different SiFAlin-modified HBPLs (SiFA = silicon fluoride acceptor), consisting of an MC1R-targeting (GG-Nle-c(DHfRWK)) and an integrin αv β3-affine peptide (c(RGDfK)), being connected by a symmetrically branching framework including linkers of differing length and composition. Kit-like18 F-radiolabeling of the HBPLs 1–6 provided the labeled products [18 F]1–[18 F]6 in radiochemical yields of 27–50%, radiochemical purities of ≥95% and non-optimized molar activities of 17–51 GBq/μmol within short preparation times of 25 min. Besides the evaluation of radiotracers regarding logD(7.4) and stability in human serum, the receptor affinities of the HBPLs were investigated in vitro on cell lines overexpressing integrin αv β3 (U87MG cells) or the MC1R (B16F10). Based on these re-sults, the most promising compounds [18 F]2, showing the highest affinity to both target receptors (IC50 (B16F10) = 0.99 ± 0.11 nM, IC50 (U87MG) = 1300 ± 288 nM), and [18 F]4, exhibiting the highest hy-drophilicity (logD(7.4) = ?1.39 ± 0.03), were further investigated in vivo and ex vivo in a xenograft mouse model bearing both tumors. For both HBPLs, clear visualization of B16F10, as well as U87MG tumors, was feasible. Blocking studies using the respective monospecific peptides demon-strated both peptide binders of the HBPLs contributing to tumor uptake. Despite the somewhat lower target receptor affinities (IC50 (B16F10) = 6.00 ± 0.47 nM and IC50 (U87MG) = 2034 ± 323 nM) of [18 F]4, the tracer showed higher absolute tumor uptakes ([18 F]4: 2.58 ± 0.86% ID/g in B16F10 tumors and 3.92 ± 1.31% ID/g in U87MG tumors; [18 F]2: 2.32 ± 0.49% ID/g in B16F10 tumors and 2.33 ± 0.46% ID/g in U87MG tumors) as well as higher tumor-to-background ratios than [18 F]2. Thus, [18 F]4 demonstrates to be a highly potent radiotracer for the sensitive and bispecific imaging of malignant melanoma by PET/CT imaging and impressively illustrates the suitability of the un-derlying concept to develop heterobivalent integrin αv β3-and MC1R-bispecific radioligands for the sensitive and specific imaging of malignant melanoma by PET/CT.

Preparation method 4 - hydroxymethylphenylboronic acid

The invention relates to the technical field of organic synthesis. The invention specifically discloses a preparation method of 4 -hydroxymethylphenylboronic acid. To the preparation method, bromobenzyl alcohol is taken as a raw material, Grignard reagent

Aerobic oxygenation of α-methylene ketones under visible-light catalysed by a CeNi3complex with a macrocyclic tris(salen)-ligand

A hetero-tetranuclear CeNi3 complex with a macrocyclic ligand catalysed the aerobic oxygenation of a methylene group adjacent to a carbonyl group under visible-light radiation to produce the corresponding α-diketones. The visible-light induced homolysis of the Ce-O bond of a bis(enolate) intermediate is proposed prior to aerobic oxygenation.

SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF

A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labe

CANCER DIAGNOSTIC IMAGING AGENTS

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

Manganese-Catalyzed Electrochemical Deconstructive Chlorination of Cycloalkanols via Alkoxy Radicals

A manganese-catalyzed electrochemical deconstructive chlorination of cycloalkanols has been developed. This electrochemical method provides access to alkoxy radicals from alcohols and exhibits a broad substrate scope, with various cyclopropanols and cyclobutanols converted into synthetically useful β- and γ-chlorinated ketones (40 examples). Furthermore, the combination of recirculating flow electrochemistry and continuous inline purification was employed to access products on a gram scale.